RS60068B1 - Liofilisani preparati melfalan flufenamida - Google Patents

Liofilisani preparati melfalan flufenamida

Info

Publication number
RS60068B1
RS60068B1 RS20200116A RSP20200116A RS60068B1 RS 60068 B1 RS60068 B1 RS 60068B1 RS 20200116 A RS20200116 A RS 20200116A RS P20200116 A RSP20200116 A RS P20200116A RS 60068 B1 RS60068 B1 RS 60068B1
Authority
RS
Serbia
Prior art keywords
lyophilized preparations
melphalan flufenamide
flufenamide
melphalan
lyophilized
Prior art date
Application number
RS20200116A
Other languages
English (en)
Inventor
Jack Spira
Fredrik Lehmann
Original Assignee
Oncopeptides Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncopeptides Ab filed Critical Oncopeptides Ab
Publication of RS60068B1 publication Critical patent/RS60068B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20200116A 2012-10-26 2013-10-24 Liofilisani preparati melfalan flufenamida RS60068B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261719184P 2012-10-26 2012-10-26
SE1251211 2012-10-26
PCT/SE2013/051246 WO2014065751A1 (en) 2012-10-26 2013-10-24 Lyophilized preparations of melphalan flufenamide
EP13849763.1A EP2928463B1 (en) 2012-10-26 2013-10-24 Lyophilized preparations of melphalan flufenamide

Publications (1)

Publication Number Publication Date
RS60068B1 true RS60068B1 (sr) 2020-05-29

Family

ID=50544986

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20200116A RS60068B1 (sr) 2012-10-26 2013-10-24 Liofilisani preparati melfalan flufenamida

Country Status (18)

Country Link
US (2) US10285946B2 (sr)
EP (2) EP3628318A1 (sr)
JP (1) JP6284945B2 (sr)
KR (1) KR102205592B1 (sr)
CN (2) CN108685860B (sr)
AU (1) AU2013335359B2 (sr)
BR (1) BR112015009280B1 (sr)
CA (1) CA2889753C (sr)
CY (1) CY1122483T1 (sr)
HK (1) HK1216501A1 (sr)
IL (1) IL238398B (sr)
MX (1) MX365205B (sr)
NZ (1) NZ708016A (sr)
PL (1) PL2928463T3 (sr)
RS (1) RS60068B1 (sr)
RU (1) RU2643762C2 (sr)
SI (1) SI2928463T1 (sr)
WO (1) WO2014065751A1 (sr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2701720B1 (en) 2011-04-28 2017-07-12 Oncopeptides AB Lyophilized preparation of cytotoxic dipeptides
JP6284945B2 (ja) 2012-10-26 2018-02-28 オンコペプティデス エービーOncopeptides AB メルファランフルフェナミドの凍結乾燥製剤
GB201507903D0 (en) 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
GB201521217D0 (en) * 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens
ES2942468T3 (es) * 2018-10-18 2023-06-01 Oncopeptides Ab Compuestos que contienen deuterio
EP3946309A1 (en) 2019-04-03 2022-02-09 Oncopeptides AB Treatment of al amyloidosis with melflufen
GB201905477D0 (en) 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
WO2021053185A1 (en) 2019-09-20 2021-03-25 Oncopeptides Ab Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma
GB202109894D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
EP4366721A1 (en) 2021-07-08 2024-05-15 Oncopeptides Innovation AB Melflufen for use in the treatment of multiple myeloma
GB202109895D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109896D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202204171D0 (en) 2022-03-24 2022-05-11 Oncopeptides Ab Novel formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8727157D0 (en) * 1987-11-19 1987-12-23 Wellcome Found Pharmaceutical formulations
DE60141398D1 (de) * 2000-06-13 2010-04-08 Oncopeptides Ab Melphalan-derivate und ihre verwendung als chemotherapeutika gegen krebs
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
WO2003035030A1 (en) * 2001-10-24 2003-05-01 Pari Gmbh Kit for the preparation of a pharmaceutical composition
US6780324B2 (en) 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US20040034099A1 (en) * 2002-06-27 2004-02-19 Ramsey Beverly J. Pharmaceutical composition
US20050152979A1 (en) 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
US7754720B2 (en) * 2006-07-07 2010-07-13 Gilead Sciences, Inc. Pyridazine compound and use thereof
PT2101731T (pt) * 2006-11-21 2018-04-18 Jina Pharmaceuticals Inc Endoxifeno para utilização no tratamento de cancro
CN101584669B (zh) * 2009-06-19 2010-12-29 江苏奥赛康药业有限公司 美法仑冻干粉针剂
WO2011078782A1 (en) * 2009-12-22 2011-06-30 Oncopeptides Ab A composition comprising of melphalan derivatives and gemcitabine or etoposide useful in the treatment of cancer
AR077384A1 (es) 2010-07-05 2011-08-24 Eriochem Sa Una formulacion farmaceutica inyectable de melfalano.
AU2012241726C1 (en) 2011-04-15 2017-09-14 Janssen Pharmaceutica Nv Freeze dried drug nanosuspensions
EP2701720B1 (en) * 2011-04-28 2017-07-12 Oncopeptides AB Lyophilized preparation of cytotoxic dipeptides
JP6284945B2 (ja) 2012-10-26 2018-02-28 オンコペプティデス エービーOncopeptides AB メルファランフルフェナミドの凍結乾燥製剤

Also Published As

Publication number Publication date
BR112015009280B1 (pt) 2022-05-31
CA2889753C (en) 2021-03-02
AU2013335359A1 (en) 2015-05-14
EP2928463B1 (en) 2019-11-20
JP6284945B2 (ja) 2018-02-28
PL2928463T3 (pl) 2020-06-01
CN108685860A (zh) 2018-10-23
MX2015005217A (es) 2015-07-14
CN104994847B (zh) 2018-08-10
CN108685860B (zh) 2022-04-05
KR102205592B1 (ko) 2021-01-20
EP3628318A1 (en) 2020-04-01
WO2014065751A1 (en) 2014-05-01
EP2928463A4 (en) 2016-08-31
US20160271065A1 (en) 2016-09-22
US10285946B2 (en) 2019-05-14
BR112015009280A2 (pt) 2017-07-04
IL238398A0 (en) 2015-06-30
MX365205B (es) 2019-05-27
HK1216501A1 (zh) 2016-11-18
US10285947B2 (en) 2019-05-14
EP2928463A1 (en) 2015-10-14
RU2015118581A (ru) 2016-12-20
CY1122483T1 (el) 2021-01-27
AU2013335359B2 (en) 2016-07-21
KR20150070375A (ko) 2015-06-24
CA2889753A1 (en) 2014-05-01
NZ708016A (en) 2018-02-23
CN104994847A (zh) 2015-10-21
US20150335578A1 (en) 2015-11-26
SI2928463T1 (sl) 2020-03-31
IL238398B (en) 2018-03-29
JP2015535243A (ja) 2015-12-10
RU2643762C2 (ru) 2018-02-05

Similar Documents

Publication Publication Date Title
HK1216501A1 (zh) 美法侖氟滅酰胺的凍干製劑
EP2900264A4 (en) GLYKOPROTEINZUBEREITUNGEN
EP2857033A4 (en) SKIN-PUNKING PEPTIDE
HK1215793A1 (zh) 的凍乾製劑
HK1203161A1 (en) Peptides and methods of using same
EP2812347A4 (en) AUTOPHAGIA-INDUCING PEPTIDE
HK1205524A1 (en) Engineered conformationally-stabilized proteins
HK1249859A1 (zh) Pcsk9肽疫苗
HK1209138A1 (en) Peptides
GB201200555D0 (en) Peptide
EP3560952C0 (en) VARIANT OF BPIFB4 PROTEIN
GB201204868D0 (en) Peptides
GB201223114D0 (en) Novel peptide
ZA201503635B (en) Lyophilized preparations of melphalan flufenamide
EP2891663A4 (en) PEPTIDE DERIVED FROM PSF1
GB201203101D0 (en) Preparations of antibacterial bisbenzimidazoles
GB201221414D0 (en) Trans-locating peptide
GB201200624D0 (en) Peptide
GB201200623D0 (en) Peptide
GB201215901D0 (en) Protein modification
GB201213672D0 (en) Protein
GB201220328D0 (en) Peptides
GB201214769D0 (en) Methodsa and peptides
GB201211740D0 (en) Peptides
GB201207895D0 (en) Peptides